Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for Multiple Myeloma

 Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for Multiple Myeloma

Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for Multiple Myeloma

Shots:

  • The approval is based on P-III OPTIMISMM study results assessing Pomalyst + bortezomib and dexamethasone vs bortezomib + dexamethasone in 559 patients in a ratio (1:1) with 2L+ MM and prior treated with/or refractory to Revlimid (lenalidomide)
  • The P-III OPTIMISMM study results: mPFS (11.2 mos. vs 7.1 mos.), reduction in diseases progression by 39%, patients with 1L therapy, mPFS (20.73 mos. vs 11.63mos.)
  • Pomalyst is an immunomodulatory therapy act by enhancing T-cell & NK-cell mediated immunity, indicated to treat MM as triple regimen therapy with Takeda’s Velcade (bortezomib) and dexamethasone

Click here to read full press release/ article | Ref: Canada Newswire | Image: QUAPE

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post